ALBANY

in Quality from Life Science Leader Magazine14:05 15.08.13


PR Newswire

ALBANY, New York, Aug. 15, 2013

ALBANY, New York, Aug. 15, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a leading contract research and manufacturing organization, announces receipt of the 2013 CMO Leadership Award for distinction in Quality from Life Science Leader, an industry-focused news publication.The award acknowledges the survey results of more than 10,000 pharmaceutical and biotechnology executives based on research conducted by Nice Insight. The survey covered more than 100 contract manufacturing organizations (CMOs). AMRI was selected as an award winner in the category of quality, which is generally defined "as a business that will treat a customer's project as if it was its own."

The Life Science Leader annual CMO Leadership Awards will be highlighted and detailed in the publication's annual CMO Leadership Awards supplement, published to coincide with the 2013 AAPS Convention in October 2013. Life Science Leader will formally present the 2013 CMO Leadership Awards at a ceremony and industry gathering in New York City on March 12, 2014.

Thomas E. D'Ambra, Ph.D., President and CEO, AMRI, said, "Quality, commitment to purpose and customer satisfaction and service are important AMRI core values that are part of our culture that we live by. To be recognized by our industry peers and customers as a leading CMO in the area of quality is a great honor and testament to the dedication of my colleagues at AMRI to each and every customer. We are grateful that our customers recognize AMRI SMARTSOURCING™ as a high quality global brand, and we will continue to search for ways to improve our offerings and performance."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at http://www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
15.08.13 11,32 11,44 10,94  10,95 $ 383.110 4,24 M

aber das wusste die 15er Nasdaq Ticker Lampe schon  

..und die schicke Ticker Lampe RT:::::: 8,539 € +4,31% +0,353 € ..buran und MfG  

11,27 $ +0,54% +0,06 $ In Euro: 8,5518 € | Nasdaq, 06.09.13

..Pott +336,82% ..buran und MfG  

http://www.ariva.de/news/...nces-Executive-Leadership-Changes-4769105 GrB  

11,56 $ +2,57% +0,29 $ In Euro: 8,7137 € | Nasdaq, 09.09.13

........TOP  

is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI


Quelle: PR Newswire
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
26.09.13 12,55 12,74 12,44  12,72 $ 168.467 2,12 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
15.10.13 12,53 12,81 12,43  12,63 $ 286.770 3,63 M

GrB  

::::::::::::::::::::::::::::::::: 9,176 € +0,12% +0,011 € ,GrB
 

Frankfurt 9,507 € Nasdaq 13,00 $ buran und MfG und tau
 

for Discovery Services08:00 16.10.13


PR Newswire

ALBANY, N.Y., Oct. 16, 2013

ALBANY, N.Y., Oct. 16, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced the appointment of Michael A. Luther, Ph.D., as Senior Vice President, Discovery, effective October 28, 2013. Dr. Luther will report to Thomas E. D'Ambra, Ph.D., President and CEO.

Dr. Luther will lead AMRI's global discovery organization, which provides biology and chemistry services to the biopharmaceutical industry, with locations in the U.S., Singapore and Hyderabad, India. Dr. Luther will also oversee AMRI's expansion into Western New York via the development of the Buffalo Medical Innovation and Commercialization Hub at Buffalo Niagara Medical Campus (BNMC Hub), a new pharmaceutical research, development and testing initiative in Buffalo, N.Y. announced by New York Governor Andrew M. Cuomo in December 2012.

Dr. Luther was most recently Corporate Vice President of Global Discovery Research Services at Charles River Laboratories, from August 2012 through September 2013, where he served as the general manager of the firm's discovery business unit, including developing and implementing strategic and operating plans. Prior to his role at Charles River, from March 2009 through August 2012, he was President and a member of the Board of Directors of the David H. Murdock Research Institute in Kannapolis, North Carolina where he led and directed all activities of the institute, which included applied R&D activities that facilitate and accelerate discovery to proof of principle and early product development in areas of human health. Prior to this, from November 2006 through March 2009 he held the position of Vice President and Site Head at Merck Frosst at their Montreal, Canada site, focused on the delivery of Phase I candidates from target to clinic for novel therapeutics in respiratory and metabolic disorders. Prior to this, from 1991 through 2006 he held positions of increasing responsibility at GlaxoSmithKline, culminating in his appointment as Vice President, High Throughput Biology.

"We are pleased and excited Dr. Luther is joining AMRI's leadership team as we continue to execute our growth strategy and move forward providing high quality services to the pharmaceutical and biotechnology industries," said Dr. D'Ambra. "Mike's strong biology background and accomplishment, as well as his experience in both large pharma and the CRO world bring to his role the experience and network to strengthen AMRI's position as a leading discovery partner to the industry. I am confident that Dr. Luther is the right person to lead AMRI's strong global discovery brand to the next level as we expand the breadth and depth of our biology capabilities in line with movement by our customers seeking greater and more integrated offerings by service providers. In addition, he is joining AMRI at an exciting time as we expand in partnership with CNSE under Governor Cuomo's leadership."

Dr. Luther earned his Ph.D. in biophysical chemistry from St. Louis University School of Medicine; an M.B.A. from Duke University, Fuqua School of Business; and a B.Sc. in biology and chemistry from North Carolina State University. Dr. Luther has authored numerous scientific papers and serves on several Boards of Directors for both academic and industry trade organizations, including the Center for Tropical and Emerging Global Diseases and the College of Life Sciences Research Foundation, North Carolina State University.

Dr. Luther succeeds Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery, who has elected to retire at the end of the year. "We thank, and are grateful to, Dr. Sargent for his long and successful career at AMRI," said Dr. D'Ambra. "Bruce joined AMRI as a Director of Medicinal Chemistry in 2001 and rose through the company to eventually become our Senior Vice President of Drug Discovery. Under Bruce's leadership, several of our internal R&D programs achieved successful milestones, some of which have been successfully out-licensed to other parties."

About AMRI



Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).





SOURCE AMRI


Quelle: PR Newswire  

14:05 23.10.13


PR Newswire

ALBANY, N.Y., Oct. 23, 2013

ALBANY, N.Y., Oct. 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue third quarter financial results before the opening of the market on Wednesday, November 6, 2013.  Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10 a.m. ET.

The conference call can be accessed by dialing 888-299-7209 (domestic calls) or 719-325-2323 (international calls) at 9:50 a.m. ET and entering passcode 5058756.  The audio webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com.  Replays of the audio webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI


Quelle: PR Newswire  

AMRI Announces Lifting of FDA Warning Letter Related to Burlington, Mass. Facility

14:05 05.11.13

PR Newswire

ALBANY, New York, Nov. 5, 2013

ALBANY, New York, Nov. 5, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced that it has received a close-out letter from the U.S. Food and Drug Administration lifting a 2010 warning letter related to its Burlington, Massachusetts aseptic fill-and-finish facility. As a result, AMRI's Burlington, Mass. facility is in a stronger position to support our customers' commercial and development programs.

Thomas E. D'Ambra, Ph.D., President and CEO, said, "AMRI is pleased to report that we have resolved all issues raised by the FDA related to our Burlington, Mass. facility. This is consistent with feedback we have received from numerous customer quality audits of our Burlington site, confirming that the corrective actions, improvements and upgrades taken at this facility provide even stronger support for our growing customer list and meet the high standards necessary to successfully operate an injectable dosage form operation. I would like to acknowledge and thank the many AMRI colleagues who have worked tirelessly and diligently to achieve this important milestone. Moving forward, we remain committed to maintaining our uncompromising focus on quality, culture and performance at Burlington and all of our locations worldwide."

The Burlington facility is an established provider of cGMP manufacturing and sterile filling of parenteral drugs using specialized technologies, including lyophilization and BUBBLE-FREE FILLING®, a unique patented technology. With its cGMP aseptic formulation and filling expertise, AMRI Burlington supports pre-clinical through commercial scale production of liquid-filled and lyophilized parenterals. These services are provided for both small molecule drug products as well as biologicals, from clinical phase to commercial scale.

In June 2013, AMRI Burlington announced that it received an expanded registration to handle Schedule II and IIN controlled substances, which are defined as drugs with a high potential for abuse with use potentially leading to severe psychological or physical dependence. This expanded registration allows Burlington to offer filling services for Schedule II, IIN, III, IIIN, IV, and V controlled substances, as well as offer services to complement more AMRI Rensselaer projects. The addition of Schedule II compounds to this registration allows Burlington to perform controlled substance work for its customers, both in the laboratory and on the engineering/production side.

Please visit the official AMRI Global YouTube channel to view a short video clip (https://www.youtube.com/watch?v=K95_v9K9JNU) featuring AMRI's Christian W. Phillips, Senior Director, Burlington Operations, who explains what the lifting of the warning letter means for AMRI Burlington and the global organization.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. AMRI's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which AMRI may not be able to predict and may not be within the AMRI's control. Factors that could cause such differences include, but are not limited to: (a) the results of further FDA inspections; (b) AMRI's ability to effectively maintain compliance with applicable FDA and DEA regulations; (c) AMRI's ability to secure additional customers for its Rensselaer and Burlington facilities; and (d) those risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission on March 18, 2013 and the Company's other SEC filings. The Company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Quelle: PR Newswire  

http://www.ariva.de/news/...and-Raises-Full-Year-EPS-Guidance-4835858 GrB  

:::::::::::::::: 13,74 $ +1,85% +0,25 $ In Euro: 10,278 € | Nasdaq, 08.11.13

Kosmonova buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.11.13     14,05     14,28§13,99 14,12 $ 72.938 1,03 M

GrB  

Date: 16-Nov-13
    Title:§Albany Molecular Research
Document Size: 6 pages
http://reports.finance.yahoo.com/w0?r=41063309:1  

8-Nov-2013

Quarterly Report
http://biz.yahoo.com/e/131108/amri10-q.html  

SK 14,12 $ SKP +0,00 Pott +447,29% ,GrB
          §  

Period Ending Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012
Total Revenue 60,755   59,292   59,406   67,212  
Cost of Revenue 44,548   42,450   37,822   48,483  
Gross Profit 16,207   16,842   21,584   18,729  
          §Operating Expenses
          §Research Development 94   171   105   106  
          §Selling General and Administrative 9,820   13,023   10,663   11,113  
          §Non Recurring 276   5,859   1,413   5,256  
              Others§-   -   -   -  
                              §
          §Total Operating Expenses -   -   -   -  
Operating Income or Loss 6,017   (2,211) 9,403   2,254  
          §Income from Continuing Operations
          §Total Other Income/Expenses Net 98   321   452   980  
          §Earnings Before Interest And Taxes 6,115   (1,890) 9,855   3,234  
          §Interest Expense 81   81   82   99  
          §Income Before Tax 6,034   (1,971) 9,773   3,135  
          §Income Tax Expense 2,104   276   3,268   1,219  
          §Minority Interest -   -   -   -  
                              §
          §Net Income From Continuing Ops 3,930   (2,247) 6,505   1,916  
          §Non-recurring Events
          §Discontinued Operations -   -   -   -  
          §Extraordinary Items -   -   -   -  
          §Effect Of Accounting Changes -   -   -   -  
          §Other Items -   -   -   -  
Net Income 3,930   (2,247) 6,505   1,916  
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares 3,930   (2,247) 6,505   1,916  
http://finance.yahoo.com/q/is?s=amri  

14.12 Up 0.07(0.50%) Nov 15, 4:00PM EST

Prev Close: 14.05
     Open:     14.09          §
      Bid:§9.80 x 100
      Ask:       N/A§
1y Target Est: 15.00
     Beta:      1.96§
Next Earnings Date: 10-Feb-14AMRI Earnings announcement
Day's Range: 13.99 - 14.28
52wk Range: 3.78 - 14.37
   Volume:    78,500§
Avg Vol (3m): 206,712
Market Cap: 426.85M
P/E (ttm): 43.31
EPS (ttm): 0.33
Div & Yield: N/A (N/A)

http://finance.yahoo.com/q?s=amri&ql=1  

AMRI Announces Proposed Private Offering of $100 Million Cash Convertible Senior Notes

23:05 18.11.13

PR Newswire

ALBANY, New York, Nov. 18, 2013

ALBANY, New York, Nov. 18, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI) ("AMRI") announced its intention to privately offer $100 million principal amount of cash convertible senior notes due 2018, subject to market and other conditions, to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). AMRI also expects to grant the initial purchasers of the notes an option to purchase up to an additional $15 million principal amount of the notes solely to cover over-allotments, if any.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint-bookrunning managers for the proposed offering.

The interest rate, conversion rate and other terms of the notes will be determined by negotiations among AMRI and the initial purchasers of the notes. When issued, the notes will be unsecured senior obligations of AMRI. AMRI expects to pay interest on the notes semi-annually on May 15 and November 15 of each year, commencing May 15, 2014. The notes will mature on November 15, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. The notes will be convertible at the option of the holders only in certain circumstances and solely into cash. The notes will not be convertible into AMRI's common stock or any other security under any circumstances. AMRI will not have the right to redeem the notes prior to maturity.

In connection with the pricing of the notes, AMRI intends to enter into privately negotiated cash convertible note hedge transactions with one or more of the initial purchasers of the notes or their respective affiliates (the "option counterparties"). The initial strike price of the cash convertible note hedge transactions is expected to be the same as the initial conversion price of the notes. AMRI also intends to enter into privately negotiated warrant transactions with the option counterparties. If the initial purchasers exercise their over-allotment option, AMRI may increase the size of the cash convertible note hedge transactions and enter into additional warrant transactions.

The cash convertible note hedge transactions are expected to offset cash payments due upon conversion of the notes in excess of the principal amount thereof in the event that the market value per share of common stock at the time of conversion of the notes is greater than the strike price under the cash convertible note hedge transactions. If, however, the market price per share of common stock exceeds the strike price under the warrant transactions as well at the time they are exercised, there would be dilution from conversion of the notes to the extent the then-current market price per share of common stock exceeds the strike price under the warrant transactions.

In connection with establishing their initial hedge of the cash convertible note hedge and warrant transactions, the option counterparties or their affiliates have advised AMRI that they expect to enter into various derivative transactions with respect to AMRI's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of AMRI's common stock or the notes at that time. In addition, the option counterparties or their affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to AMRI's common stock and/or purchasing or selling AMRI's common stock or other securities of AMRI in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of AMRI's common stock or the notes.

AMRI expects to use a portion of the net proceeds from the offering of the notes to pay the cost of the cash convertible note hedge transactions (after such cost is partially offset by the proceeds from the sale of the warrants). The remaining net proceeds from the offering may be used for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services, technologies and capital expenditures.

The notes have not been and will not be registered under the Securities Act or the securities laws of any state or other jurisdiction and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws of any relevant state or jurisdiction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. AMRI gives no assurance that the proposed offering can be completed on any terms.
Quelle: PR Newswire  

Convertible Senior Notes

13:05 20.11.13

PR Newswire

ALBANY, New York, Nov. 20, 2013

ALBANY, New York, Nov. 20, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI) ("AMRI") announced that it has upsized to $130.0 million principal amount and priced its previously announced private offering of cash convertible senior notes due 2018 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). AMRI also granted the initial purchasers of the notes an option to purchase up to an additional $20.0 million principal amount of the notes solely to cover over-allotments, if any.

When issued, the notes will be unsecured senior obligations of AMRI and bear interest at a rate of 2.25% per annum, payable semi-annually on May 15 and November 15 of each year, commencing May 15, 2014. The notes will mature on November 15, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. The notes will be convertible at the option of the holders only in certain circumstances and solely into cash. The notes will not be convertible into AMRI's common stock or any other security under any circumstances. AMRI will not have the right to redeem the notes prior to maturity. The conversion rate for the notes will initially be 63.9844 shares of AMRI's common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $15.63 per share of AMRI's common stock. The initial conversion price of the notes represents a premium of approximately 32.0% to the $11.84 per share last reported sale price of AMRI's common stock on November 19, 2013. The offering of the notes is expected to close on November 25, 2013, subject to customary closing conditions.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint-bookrunning managers for the offering.

In connection with the pricing of the notes, the Company entered into privately negotiated cash convertible note hedge transactions with one or more of the initial purchasers of the notes or their respective affiliates (the "option counterparties"). The initial strike price of the cash convertible note hedge transactions is approximately $15.63 per share of common stock (the same as the initial conversion price of the notes). The Company also entered into privately negotiated warrant transactions with the option counterparties, with an initial strike price of approximately $18.94 per share of common stock. If the initial purchasers exercise their over-allotment option, the Company may increase the size of the cash convertible note hedge transactions and enter into additional warrant transactions.

The cash convertible note hedge transactions are expected to offset cash payments due upon conversion of the notes in excess of the principal amount thereof in the event that the market value per share of common stock at the time of conversion of the notes is greater than the strike price under the cash convertible note hedge transactions. If, however, the market price per share of common stock exceeds the strike price under the warrant transactions as well at the time they are exercised, there would be dilution from conversion of the notes to the extent the then-current market price per share of common stock exceeds the strike price under the warrant transactions.

In connection with establishing their initial hedge of the cash convertible note hedge and warrant transactions, the option counterparties have advised the Company that they or their affiliates expect to enter into various derivative transactions with respect to the Company's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company's common stock or the notes at that time. In addition, the option counterparties have advised the Company that they or their affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company's common stock and/or purchasing or selling the Company's common stock or other securities of the Company in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of the Company's common stock or the notes.

AMRI estimates that the net proceeds from the offering of the notes will be approximately $125.8 million (or approximately $145.3 million if the initial purchasers exercise their over-allotment option in full), after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by AMRI. AMRI expects to use a portion of the net proceeds from the offering of the notes to pay the cost of the cash convertible note hedge transactions (after such cost is partially offset by the proceeds from the sale of the warrants). The remaining net proceeds from the offering may be used for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services, technologies and capital expenditures.

The notes have not been and will not be registered under the Securities Act or the securities laws of any state or other jurisdiction and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws of any relevant state or jurisdiction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. AMRI gives no assurance that the proposed offering can be completed on any terms.





Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.11.13 11,70 11,70 11,19   11,27 $ 2.832.220 23,2 M

GrB